Peking Union Medical College Hospital
Beijing, China
NCT Number: NCT05369221
In this study, 5 subjects will be enrolled and the cumulative D2cc dose for rectum during brachytherapy will be recorded as the primary outcome measures.
Looking for future studies?
Notify Me18 year–75 year
Female
Interventional
Phase 1
Beijing, China
This is a phase I prospective study of 5 patients to determine if PEG hydrogel (ReSpace™) reduces the radiation dose delivered to the rectum during radiation therapy for cervical cancer by increasing the space between the cervix and the anterior rectal wall. In the other word, the purpose of this study is to assess whether the use of ReSpace™ hydrogel results in a reduction of radiation exposure to the anterior rectum.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All of the subjects will be injected with ReSpace™ hydrogel.
Time frame: 21 days post index procedure
The mean of the cumulative rectum D2cc dose during brachytherapy will be calculated for subjects. which will be used to validate the parameter selection for phase II sample size estimation.
Time frame: during procedure
The success rate of hydrogel spacer implantation will be evaluated by the investigator for subjects.
Time frame: during procedure
The ease of use of the test device will be evaluated by the investigator on the day of Operation. The evaluation items are as follows:
Time frame: during procedure
Recording the amount of hydrogel spacer injected in the subjects,which will be used to evaluate the reasonableness of the injected dose of ReSpace™ when hydrogel is injected between the rectum and cervix in women undergoing radiation therapy.
Peking Union Medical College Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04557423
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04221945
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Phoenix, Arizona, United States
View Trial DetailsNCT05007106
Adenocarcinoma, Adnexal Diseases
Anchorage, Alaska, United States
View Trial DetailsNCT04694495
Communicable Diseases, DNA Virus Infections
Hefei, Anhui, China
View Trial Details